Results 31 to 40 of about 3,657 (192)

Stability Indicating HPLC Method for the Determination of Delamanid in Pharmaceutical Dosage Form [PDF]

, 2021
Delamanid is successfully used for treatment of MDR TB. A stability indicating analytical method has been developed and validated. In this study Delamanid was degraded under different stress test conditions as per International Conference on ...
Patel, Advaita B., Patel, Deepa R., Babaria, Mansi, Patel, Dhaval M.   +3 more
core   +1 more source

Early experience of delamanid in extensively drug-resistant pulmonary tuberculosis

Lung India, 2023
Tuberculosis is a leading cause of death in our country. Multidrug-resistant tuberculosis increases the morbidity and mortality due to severe manifestations and difficult and prolonged medications.
Vikas Marwah, Prashant R Patil, Robin Choudhary, Virender Malik   +3 more
doaj   +1 more source

Injectable-free regimens containing bedaquiline, delamanid, or both for adolescents with rifampicin-resistant tuberculosis in Khayelitsha, South Africa

EClinicalMedicine, 2020
Background: Limited data exist on the use of bedaquiline and delamanid in adolescents with rifampicin-resistant tuberculosis (RR-TB). We describe RR-TB treatment of adolescents (10–19 years) with injectable-free regimens containing these drugs in ...
Erika Mohr-Holland, Anja Reuter, Jennifer Furin, Anthony Garcia-Prats, Virginia De Azevedo, Vanessa Mudaly, Yulene Kock, Laura Trivino-Duran, Petros Isaakidis, Jennifer Hughes   +9 more
doaj   +1 more source

Outcomes of Multidrug-Resistant Tuberculosis Treated With Bedaquiline or Delamanid

, 2021
Background. Since 1 September 2016, bedaquiline and delamanid have been administered for the treatment of patients with multidrug-resistant/rifampicin-resistant tuberculosis after the official approval in South Korea.
Hyungseok Kang, Jeon, Doosoo, Yong-Soo Kwon, Hwang, Hyeontaek, Shim, Tae Sun, Yim, Jae-Joon, 심태선, Doosoo Jeon, Jae-Joon Yim, Hyeontaek Hwang, Kang, Hyungseok, Kwon, Yong-Soo   +11 more
core   +1 more source

Short course treatment of pulmonary tuberculosis patients suffering from multiple drug resistance. The current situation and future perspectives

Туберкулез и болезни лёгких, 2021
The article presents a review of 70 publications. It describes relevant data on drugs, timing, indications, efficacy, and safety of short-term treatment regimens for multiple drug resistant tuberculosis.
A. E. Russkikh, D. M. Kutuzova, O. V. Lovacheva, A. G. Samoylova, I. A. Vasilyeva   +4 more
doaj   +1 more source

Specific Parameters of Toxic Reactions in Rats to the Combination of Delamanid and Drugs for Treatment of Drug Resistant Tuberculosis (A Pilot Study)

Туберкулез и болезни лёгких, 2023
The objective: to evaluate the toxicity of combinations of delamanid and drugs for treatment of drug resistant tuberculosis with different safety profiles in an experiment.Results.
G. N. Mozhokina, L. Yu. Petrova, A. G. Samoylova, A. V. Abramchenko   +3 more
doaj   +1 more source

Therapeutic Failure and Acquired Bedaquiline and Delamanid Resistance in Treatment of Drug-Resistant TB

Emerging Infectious Diseases, 2023
New classes of antitubercular drugs, diarylquinolines and nitroimidazoles, have been associated with improved outcomes in the treatment of drug-resistant tuberculosis, but that success is threatened by emerging drug resistance.
James Millard, Stephanie Rimmer, Camus Nimmo, Max O’Donnell   +3 more
doaj   +1 more source

The Prospective Synergy of Antitubercular Drugs With NAD Biosynthesis Inhibitors

Frontiers in Microbiology, 2021
Given the upsurge of drug-resistant tuberculosis worldwide, there is much focus on developing novel drug combinations allowing shorter treatment duration and a lower toxicity profile.
Kyle H. Rohde, Leonardo Sorci
doaj   +1 more source

Predicting nitroimidazole antibiotic resistance mutations in Mycobacterium tuberculosis with protein engineering.

PLoS Pathogens, 2020
Our inability to predict which mutations could result in antibiotic resistance has made it difficult to rapidly identify the emergence of resistance, identify pre-existing resistant populations, and manage our use of antibiotics to effectively treat ...
Brendon M Lee, Liam K Harold, Deepak V Almeida, Livnat Afriat-Jurnou, Htin Lin Aung, Brian M Forde, Kiel Hards, Sacha J Pidot, F Hafna Ahmed, A Elaaf Mohamed, Matthew C Taylor, Nicholas P West, Timothy P Stinear, Chris Greening, Scott A Beatson, Eric L Nuermberger, Gregory M Cook, Colin J Jackson   +17 more
doaj   +1 more source

Scoping review: QT interval prolongation in regimen containing bedaquiline and delamanid in patients with drug-resistant tuberculosis

International Journal of Mycobacteriology, 2022
Background: A regimen containing bedaquiline–delamanid is recommended in management of drug-resistant tuberculosis (DR TB) to increase a success rate.
Oki Nugraha Putra, Yulistiani Yulistiani, Soedarsono Soedarsono   +2 more
doaj   +1 more source